205 related articles for article (PubMed ID: 16096413)
1. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study.
Downs-Kelly E; Yoder BJ; Stoler M; Tubbs RR; Skacel M; Grogan T; Roche P; Hicks DG
Am J Surg Pathol; 2005 Sep; 29(9):1221-7. PubMed ID: 16096413
[TBL] [Abstract][Full Text] [Related]
2. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM
J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821
[TBL] [Abstract][Full Text] [Related]
3. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
Moelans CB; de Weger RA; van Diest PJ
Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
[TBL] [Abstract][Full Text] [Related]
4. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
[TBL] [Abstract][Full Text] [Related]
5. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
Shah SS; Wang Y; Tull J; Zhang S
Diagn Mol Pathol; 2009 Mar; 18(1):30-3. PubMed ID: 19214111
[TBL] [Abstract][Full Text] [Related]
6. Impact of polysomy 17 on HER2 testing of invasive breast cancer patients.
Liu Y; Ma L; Liu D; Yang Z; Yang C; Hu Z; Chen W; Yang Z; Chen S; Zhang Z
Int J Clin Exp Pathol; 2014; 7(1):163-73. PubMed ID: 24427336
[TBL] [Abstract][Full Text] [Related]
7. HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere.
Panvichian R; Tantiwetrueangdet A; Wongwaisayawan S; Nampoon A; Lertsithichai P; Leelaudomlipi S
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):367-74. PubMed ID: 22417858
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
[TBL] [Abstract][Full Text] [Related]
9. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
10. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.
Vranic S; Teruya B; Repertinger S; Ulmer P; Hagenkord J; Gatalica Z
Cancer; 2011 Jan; 117(1):48-53. PubMed ID: 20803611
[TBL] [Abstract][Full Text] [Related]
11. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR
Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995
[TBL] [Abstract][Full Text] [Related]
12. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
Jiang H; Bai X; Zhao T; Zhang C; Zhang X
Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636
[TBL] [Abstract][Full Text] [Related]
13. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.
Varga Z; Tubbs RR; Wang Z; Sun Y; Noske A; Kradolfer D; Bosshard G; Jochum W; Moch H; Öhlschlegel C
Breast Cancer Res Treat; 2012 Apr; 132(3):925-35. PubMed ID: 21698407
[TBL] [Abstract][Full Text] [Related]
14. [HER2 status in breast cancer of Chinese women: a study of 1170 cases using fluorescence in-situ hybridization].
Zeng X; Liang ZY; Wu SF; Gao J; Zhou WX; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2008 Sep; 37(9):594-8. PubMed ID: 19094582
[TBL] [Abstract][Full Text] [Related]
15. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
[TBL] [Abstract][Full Text] [Related]
16. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
Vanden Bempt I; Van Loo P; Drijkoningen M; Neven P; Smeets A; Christiaens MR; Paridaens R; De Wolf-Peeters C
J Clin Oncol; 2008 Oct; 26(30):4869-74. PubMed ID: 18794552
[TBL] [Abstract][Full Text] [Related]
17. Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations.
Lambein K; Praet M; Forsyth R; Van den Broecke R; Braems G; Matthys B; Cocquyt V; Denys H; Pauwels P; Libbrecht L
J Clin Pathol; 2011 Mar; 64(3):200-7. PubMed ID: 21177747
[TBL] [Abstract][Full Text] [Related]
18. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.
Dal Lago L; Durbecq V; Desmedt C; Salgado R; Verjat T; Lespagnard L; Ma Y; Veys I; Di Leo A; Sotiriou C; Piccart M; Larsimont D
Mol Cancer Ther; 2006 Oct; 5(10):2572-9. PubMed ID: 17041102
[TBL] [Abstract][Full Text] [Related]
19. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
20. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
